As previously reported, the Federal Court of Appeal (FCA) dismissed Apotex’s appeal of a judicial review decision of the Therapeutic Products Directorate (TPD) which required Apotex to submit additional information concerning products manufactured or tested in Apotex’s facilities in India. The FCA found that the Federal Court made no reviewable error in its conclusion that the TPD’s decision was not improperly motivated. On February 22, 2019, the Supreme Court dismissed Apotex’s application for leave to appeal (docket No. 38336).
Related Publications & Articles
-
Health Canada’s Action Plan for non-prescription drugs
As part of Health Canada’s initiative to update its approach to regulating self-care products, including non-prescription drugs, and as a first step in advance of a regulatory proposal to simplify mar...Read More -
Federal Court dismisses Takeda’s motion to consolidate two dexlansoprazole PMNOC actions against Apotex
On January 23, 2023, the Federal Court released a decision by Associate Judge Tabib denying Takeda’s motion to consolidate two actions commenced under the Patented Medicines (Notice of Compliance) Reg...Read More -
Federal Court concludes Minister of Health’s decision not to reassess data protection for SPRAVATO in view of CUSMA is reasonable
On January 5, 2023, Justice Manson found that the Minister’s decision was reasonable and dismissed Janssen’s application: Janssen Inc v Canada (Attorney General), 2023 FC 7.Read More